Chemotherapy: Open Access
Open Access
ISSN: 2167-7700
ISSN: 2167-7700
Hiroyuki Osada, Hiroki Hayase, Yushi Futamura, Toshihiko Nogawa, Wierzba Konstanty and Nobumoto Watanabe
Scientific Tracks Abstracts: Chemotherapy
Malaria is one of the most serious infectious diseases. Since parasite strains resistant to traditional antimalarial drugs such as chloroquine (CLQ) and artemisinin (ART) derivatives appeared, novel antimalarial agents are required to be developed urgently. I will introduce the screening method and the hit compounds showing the antimalarial activity in this presentation. It is known that malaria parasite has high LDH activity. We established a HTS system using the LDH assay to isolate growth inhibitors of the parasite strain 3D7 cultured in vitro. Using this system, we selected 450 compounds from 17,000 compounds of RIKEN NPDepo (Natural Products Depository) chemical library with 5 μg/mL or less IC90 activity of parasite growth. As the second screening, we evaluated the toxicity toward mouse NIH3T3 and rat NRK cells of these compounds. Eighty six compounds showed selective inhibition against parasite with IC50 values lower than one thirtieth of those toward mammalian cells. Finally, as the third screening, we examined growth inhibitory effect of these 86 compounds on the CLQ resistant parasite strains (K1 and Dd2) and found that 36 compounds were as effective on the resistant strains as on 3D7 strain. NPD10928 (IC50 88 nM) was selected as one of the potent inhibitors against malaria parasites. We administrated NPD10928 to a malaria infectious mouse (ip, 20 mg/kg), and found that the growth of parasite was reduced significantly. In addition, I will introduce other antimalarial agents that were found by our screening.
Hiroyuki Osada is a Deputy Director of RIKEN Center for Sustainable Resource Science. He completed his education from The University of Tokyo in Department of Agricultural Chemistry. He is Editorial Member of different journals. He also published more than 9 research papers.